Researchers have discovered that SGLT2 inhibitors, a class of drugs originally developed to treat diabetes and now widely used for heart failure, work by activating a key enzyme that helps heart cells produce and use energy more efficiently. The study, published today in Science, potentially solves a longstanding gap in knowledge about these drugs and opens the door to potential new treatments for heart failure.
Discover Recifes.net
This story is part of Recifes international coverage. Explore the platform and follow us — new English social channels come next.
